Loading...
•
Sep 30, 2022
Repare Therapeutics Q3 2022 Earnings Report
Reported financial results for the third quarter ended September 30, 2022.
Key Takeaways
Repare Therapeutics reported net income of $75.5 million, or $1.71 diluted earnings per share, and held $370.4 million in cash and cash equivalents and marketable securities as of September 30, 2022. The company believes this will be sufficient to fund planned operations into 2026.
Early Phase 1 clinical data readout for RP-6306 is expected in the first half of 2023
Camonsertib development is advancing with Roche under worldwide license and collaboration agreement
IND-enabling studies for RP-2119, a Polθ inhibitor, are currently underway and on track for trial start in summer 2023
Company is well positioned to advance clinical programs and portfolio, with $370.4 million in cash and cash equivalents and marketable securities and funding into 2026
Repare Therapeutics
Repare Therapeutics
Forward Guidance
Repare Therapeutics is focused on advancing its pipeline of programs and initiating clinical trials for new molecules.
Positive Outlook
- Expected data readout for RP-6306 in the first half of 2023.
- Initiation of clinical testing of a new carboplatin combination with RP-6306 in 2023.
- Advancement of RP-2119, with clinical trials expected to start next summer.
- Initiation of IND-enabling studies for an additional small molecule in the first half of 2023.
- Collaboration with Roche for the development and commercialization of camonsertib.